Navigation Links
Treatment with an anti-psychotic drug found to cause changes in metabolism earlier than expected
Date:4/7/2008

SAN DIEGO, CA Schizophrenia is a complex type of psychotic mental illness characterized by thoughts that are uncoupled from reality. Huge gains in the effective treatment of individuals with the disease began in the 1950s with the development of the first generation of antipsychotic drugs. The medications allowed physicians to treat the positive effects of the illness (delusions and hallucinations) and, to a lesser extent, the negative symptoms (apathy). The second generation of antipsychotics known as atypical antipsychotics (AAP) began in 1990. These newer medicines have proven as effective in treating the positive aspects of the disease and more effective in combating the negative ones.

As is the case with nearly all medications, antipsychotics have side affects, including weight gain and some other risk factors of metabolic syndrome, which puts an individual at greater risk of heart disease and type 2 diabetes. Physicians are concerned that these side effects will cause their patients to stop taking their medications.

A team of French researchers has now found in an animal model that consuming at least one of the AAPs exhibit some of the risks related to metabolic syndrome that are similar to those found in patients. This model allows researchers to explore the sequence of early metabolic events that result from AAP treatment.

Presentation at the 121st Annual Meeting of the American Physiological Society

Montserrat Victoriano, Gilles Fromentin, Jean-Francois Huneau, and Dominique Hermier of the Department of Human Nutrition, INRA, Paris, France; and Renaud de Beaurepaire, Department of Psychopharmacology, Hospital Paul Guiraud, Villejuif, France, conducted the study. It is entitled Energy Metabolism Disturbances Induced by Antipsychotic Treatment in a Rat Model. Dr. Hermier will present the teams findings at the 121st annual meeting of the American Physiological Society (APS; www.the-APS.org/press), part of the Experimental Biology 2008 scientific conference.

Summary of the Study

The researchers had previously developed a model for antipsychotic-induced weight gain in the male rat, which allowed them to clearly distinguish between those antipsychotic drugs that produce some weight gain, moderate weight gain or no gain at all. These distinctions corresponded to the response in humans. Their latest study is built on these findings.

In the latest study they used 18 male rats which were randomly assigned to one of three groups: (1) those receiving the conventional antipsychotic drug haloperidol (HA); (2) those receiving the atypical antipsychotic drug olanzapine (OL); or (3) the control (CO) group which did not receive either drug. The medicines were given in food for a period of six weeks. Female rats were excluded to eliminate bias in the study since antipsychotic-induced weight gain in female rodents is likely related to an interaction of the drugs with estrogens.

Testing after four weeks found that the concentration of blood sugar (as glucose) was higher in OL rats (0.87 g/l) than in CO rats (0.75 g/l) and the levels increased more rapidly after a glucose meal. Testing six weeks later found fasting blood sugar levels continued to rise in OL rats (1.46 g/l vs. 1.25 g/l in CO rats) while the level of lipids (fats) in the blood was similar for both groups. Although there was no difference in body weight gain or food intake, the proportion of fat stored in the abdominal cavity was higher in OL rats (1.63%) vs. CO rats (1.44%).

The HA rats did not vary in any way with the control group at any time. They exhibited a lower blood sugar level after a glucose meal and a lower proportion of intraabdominal fat store (1.44%) than OL rats.

Conclusions

Senior study author Dominique Hermier said, Based on these findings we concluded that male rats treated with olanzapine experienced an early disruption of energy metabolism. This was a result of the fat tissue we observed and the impairment in blood sugar regulation which are both associated with metabolic syndrome and subsequent risk of diabetes.

She added, Atypical medications like olanzapine are of tremendous value in treating individuals with certain kinds of mental illness. Our hope is that through discoveries such as this one, such life-enhancing medicines can be further optimized.


'/>"/>

Contact: Donna Krupa
DKrupa@the-aps.org
619-525-6202
American Physiological Society
Source:Eurekalert

Related medicine news :

1. Identification of dopamine mother cells could lead to future Parkinsons treatments
2. Did Medicare Reimbursement Changes Affect Prostate Cancer Treatment?
3. FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
4. Enzyme complex could be key to new cancer treatments
5. Pollin Pediatric Research Prize awarded for discovery of lifesaving treatment of RDS
6. Women Can Now Learn About Minimally Invasive Gynecologic Treatments at AAGL.org
7. New Breakthrough Treatment is Tough On Lice But Gentle On Kids
8. Genomic Profiling of Breast Cancers a Better Treatment Tool
9. Elderly Can Benefit From High Blood Pressure Treatment
10. Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly
11. Many Women Unclear About Breast Cancer Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... countries to hospitals in the United States, it’s a threat that is constantly ... obstacles facing infection prevention and offers strategies for the healthcare community to help ...
(Date:3/24/2017)... ... ... According to a new study by NCPA Senior Fellow John R. Graham, "the ... has directed the CBO to follow. The CBO itself previously recognized Obamacare would kill ... a reduction in employer-based coverage due to the GOP reform, which is not plausible. ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... and related services to families and business owners across eastern Michigan, is connecting ... regional families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works ...
(Date:3/24/2017)... ... March 24, 2017 , ... As the standards ... a communications platform that positions them as the go-to thought leader in all ... online publication as an always-on, always-fresh news, views and advocacy engine, called ONS ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of ... is pleased to announce Westchester resident Lauren C. Enea has joined the firm as ... firm, will concentrate her practice in elder law, Medicaid planning and applications, and Wills, ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... Growth and Demand Forecast to 2022" report to their offering. ... The global wound care market ... at a CAGR of 6.7% during 2016-2022 Among the various ... largest share in the global market in 2015. Among the various applications, ...
(Date:3/24/2017)... -- FinancialBuzz.com News Commentary  ... According to new data published ... the legal cannabis market is projected to continue to grow ... from the current presidential administration. The report created by Arcview,s ... of growth in this industry are the passage and subsequent ...
(Date:3/24/2017)... -- Global Ampoules Market report provides a ... and industry chain structure. The Ampoules market analysis is ... landscape analysis, and major regions, development status. ... Complete ... 10 company profiles and 183 tables and figures is ...
Breaking Medicine Technology: